



S5 Fig. The pattern of time to onset (A, B) and resolution (C, D) of all-grade irAEs for patients treated by IPI monotherapy (A, C) and IPI plus conventional therapy (B, D). Circles and bars represent median values and 95% confidence intervals, respectively. Number and percent of an event indicate the incidence of the irAE (A, B) and patients whose irAE resolved (C, D). CT, conventional therapy; IPI, ipilimumab; IrAEs, immune-related adverse events. ^{a)} $p < 0.05$ between the comparison of time to onset related to IPI monotherapy and IPI plus conventional therapy, ^{b)} $p < 0.05$ between the comparison of time to resolution related to IPI monotherapy and IPI plus conventional therapy. A total of 2,092 and 2,123 patients were included in the analysis of time to onset and resolution, respectively, for IPI monotherapy; 866 and 488 patients for IPI plus conventional therapy.